Budapest, Hungary

Gábor Ambrus

This inventor holds 1 USPTO granted patent. Top assignee: Ivax International Gmbh. Active years: 2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gábor Ambrus. Retrieved from https://idiyas.com/inventor/gandaacutebor-ambrus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gábor Ambrus: Innovator in Angiogenesis Inhibition

Introduction

Gábor Ambrus is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit angiogenesis. His work is crucial in the fight against tumor growth and metastasis.

Latest Patents

Gábor Ambrus holds a patent for "Heterocyclic compounds inhibiting angiogenesis." This invention relates to compounds of general formula (I), where R represents various groups, including alkyl and cycloalkyl groups. The compounds are designed to inhibit neovascularization in living tissues, making them valuable in preventing tumor growth and the formation of metastases. His patent is a testament to his innovative approach to addressing critical health challenges.

Career Highlights

Ambrus is associated with Ivax International GmbH, where he applies his expertise in pharmaceutical development. His work has led to advancements in the creation of effective angiogenesis inhibitors, showcasing his commitment to improving medical treatments.

Collaborations

Gábor Ambrus has collaborated with notable colleagues, including Nándor Makk and Anikó Tegdes. These partnerships have contributed to the success of his research and the development of innovative solutions in the pharmaceutical industry.

Conclusion

Gábor Ambrus is a distinguished inventor whose work in angiogenesis inhibition has the potential to transform cancer treatment. His contributions to the field are invaluable, and his ongoing research continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…